May 7, 2012
Steepest Decline Yet In HPV Vaccine Completion Rate Thanks To Informed Parents
Thanks to the wealth of information available on the HPV vaccine fraud, the proportion of insured girls and young women completing the human papillomavirus (HPV) vaccine among those who initiated the series has dropped significantly -- as much as 63 percent -- since the vaccine was approved in 2006, according to new research from the University of Texas Medical Branch (UTMB) in Galveston.
The study, published in the current issue of Cancer, reveals the steepest decline in vaccine completion among girls and young women aged nine to 18 -- the age group according to medical officials that should receive the vaccine in three doses over six months -- a message that has been drilled into parents for just over five years.
Researchers examined a large health insurance company’s records of 271,976 female patients aged nine and older who received the first dose of the HPV vaccine between 2006 and 2009. Of this full sample, just 38.2 percent received all three doses within 365 days. Researchers uncovered a marked drop in the number of females who completed the vaccine series:
HPV Vaccine Completion Rates
Age 2006 2009 Completion Dec/Inc
- 9-12 57.5% 21.2% --> 63%
- 13-18 54.9% 20.8% --> 62%
- 19-26 44.3% 22.6% --> 49%
Natural health experts are attributing the victory to mostly informed parent among the 9-12 and 13-18 age groups, where the drop may be mostly due to information presented on the internet included well balanced studies that have exposed gardasil and HPV vaccinations as unproven, unjustified and lacking evidence-based medicine.
The problem is, vaccinations such as HPV are not preventative, they do compromise safety and physicians will never provide accurate explanations of vaccine risks and benefits because they do not know themselves. Physicians can only rely on the information from vaccine manufacturers and since long-term pharmacokinetic effects which study the bodily absorption, distribution, metabolism and excretion of vaccines and their ingredients are never examined or analyzed, a Physician can never fully inform of patient of ANY benefits or risks.
Gardasil s manufacturer, Merck, states on their website that Gardasil does more than help prevent cervical cancer, it protects against other HPV diseases, too. Merck further claims that Gardasil does not prevent all types of cervical cancer. Similarly, the US CDC and the FDA claim that This [Gardasil] vaccine is an important cervical cancer prevention tool that will potentially benefit the health of millions of women and based on all of the information we have today, CDC recommends HPV vaccination for the prevention of most types of cervical cancer. All four of these statements are at significant variance with the available evidence as they imply that Gardasil can indeed protect against some types of cervical cancer.
At present there are no significant data showing that either Gardasil or Cervarix (GlaxoSmithKline) can prevent any type of cervical cancer since the testing period employed was too short to evaluate long-term benefits of HPV vaccination. The longest follow-up data from phase II trials for Gardasil and Cervarix are 5 and 8.4 years, respectively, while invasive cervical cancer takes up to 20 -40 years to develop from the time of acquisition of HPV infection.
Accurate and effective communication with parents about the dangers of the HPV vaccine is being achieved mostly throught the internet as mainstream medical physicians are accepting the results of studies that show the opposite of what regulatory medical colleges and associations are recommending.
Persistent HPV infections caused by high-risk HPVs will usually not lead to immediate precursor lesions, let alone in the longer term to cervical cancer. The reason for this is that as much as 90% HPV infections resolve spontaneously within 2 years and, of those that do not resolve, only a small proportion may progress to cancer over the subsequent 20 - 40 years. Moreover, research data show that even higher degrees of atypia can either resolve or stabilize over time. Thus, in the absence of long-term follow-up data, it is impossible to know whether HPV vaccines can indeed prevent some cervical cancers or merely postpone them.
It will be important for future studies to continue to identify the lack of evidence based medicine and the true motives for the profit-based vaccine which has nothing to do with advancing the health of young girls or boys.
Dave Mihalovic is a Naturopathic Doctor who specializes in vaccine research, cancer prevention and a natural approach to treatment.